Credence MedSystems Receives a Strategic Investment From One of the World’s Leading Pharmaceutical Companies
26.1.2021 09:07:00 EET | Business Wire | Press release
Credence MedSystems announced today that Novartis has made a strategic investment in the Company. The investment will advance ongoing development and scaling of Credence’s innovative drug delivery systems, with an initial focus on the Credence Companion® Safety Syringe System. With the investment in Credence, Novartis seeks to support its patients, caregivers, and healthcare professionals by enhancing the safety and user experience during administration of Novartis injectable medications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005138/en/
The Credence Companion allows pharmaceutical manufacturers to provide critical usability and safety features to their end-users. At the completion of the injection, the user receives end-of-dose cues indicating that the full dose has been delivered, and the needle automatically retracts into the syringe barrel. The enhanced usability can contribute to improved adherence, while the passive needle retraction helps protect users from accidental needlesticks and prevents reuse of the syringe.
Credence Companion technology integrates with the syringe before the medication is filled. To facilitate implementation for pharmaceutical manufacturers and offer this technology for a variety of applications and therapeutic fields, a fully integrated solution that is compatible with various syringe barrels is a prerequisite. The integrated approach to safety, where no additional devices need to be assembled after syringe filling, brings operational efficiencies to drug manufacturers. In support of this more efficient approach to the market, a collaboration between Credence and SCHOTT AG for the application of Credence Companion technology with SCHOTT’s pre-fillable glass and polymer syringe systems has recently been announced.
Jeff Tillack and John Merhige, Credence’s COO and CCO, jointly stated, “We are excited to welcome Novartis as a strategic investor. This represents an important validation of Credence technology in the market and helps support our continued growth. We look forward to working together with Novartis to improve the user experience and contribute to better patient outcomes.”
About Credence MedSystems, Inc.
Credence MedSystems is an innovator of drug delivery systems that solve unmet market needs for the pharmaceutical industry. Credence’s philosophy of Innovation Without Change allows pharma manufacturers to impress and protect their end users while preserving their existing processes, sourcing strategies and preferred primary package components. The Companion® family of syringe systems includes proprietary needle retraction technology, syringe reuse prevention and other critical safety and usability features. The Dual Chamber Reconstitution platform offers single-step mixing and injection for medicines that require reconstitution at the time of delivery. The Credence Connect™ brings digital connectivity to any prefilled syringe. Metered dose systems and other novel devices address the needs of specific therapeutic markets such as ocular therapies and cosmetic applications.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005138/en/
Contact information
John A. Merhige
jmerhige@credencemed.com
www.CredenceMed.com
+1-844-263-3797 (844-CMEDSYS)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Introduces Symbiosis: an AI-Driven Operating Model to Align Business Priorities and AI-Accelerated Delivery14.10.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY] introduces Symbiosis, an AI-driven operating model designed for enterprises integrating generative AI and agentic systems into their operating processes. Supported by a dedicated platform, Symbiosis connects strategy, portfolio management and execution, helping organisations align priorities and investment decisions with measurable business outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014833053/en/ Reply introduces Symbiosis, an AI-driven operating model designed for enterprises integrating generative AI and agentic systems into their operating processes. Supported by a dedicated platform, Symbiosis connects strategy, portfolio management and execution, helping organisations align priorities and investment decisions with measurable business outcomes. As AI enables teams to develop, test and deliver solutions faster, organisations also need to adapt how they decide where to focus that cap
SIAL Paris 2026: Food Sovereignty, AI, Personalised Nutrition… Three Major Debates to Shape the Future of Food14.10.2026 10:35:00 EEST | Press release
More than just a major business event, SIAL Paris is also a forum for reflection, analysis and inspiration for the entire food sector. Over five days, several stages will bring together leaders, experts, manufacturers, retailers, researchers and entrepreneurs to analyse the sector’s transformations and, above all, to identify concrete courses of action. Food sovereignty, artificial intelligence, geopolitics, new consumption models, personalised nutrition and the transformation of the value chain: the 2026 edition offers a particularly rich programme, featuring conferences, keynote speeches, round-table discussions, pitches and case studies. SIAL Summits: three major events to understand today and prepare for tomorrow At the heart of this programme, the SIAL Summits, held in Hall 5A, offer three premium 2½-hour sessions dedicated to the strategic challenges reshaping the agri-food industry. Designed as genuine platforms for discussion and reflection, they will bring together experts and
Otometrics Launches Aurical® IQ – Delivering the First and Only Guided Workflow Enabling up to 51% Faster Fittings and 39% Improved Workflow Accuracy14.10.2026 10:00:00 EEST | Press release
Otometrics, the Hearing & Balance division of Natus Sensory, today announced Aurical® IQ, the next generation of its trusted hearing aid fitting and verification platform. Combining the first and only Guided Workflow for hearing aid fitting and verification, support for the NAL-NL3 Fitting System and a redesigned Otosuite® software experience, Aurical IQ is designed to help hearing care professionals work more efficiently and follow best-practice fitting procedures with greater consistency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014023398/en/ Aurical IQ Guided Workflow provides structured, step-by-step guidance through the fitting and verification process, designed to make best-practice fitting easier to follow. A new chapter of innovation for Otometrics Clinical evaluations demonstrated measurable benefits for clinicians at different levels of experience. Experienced clinicians achieved up to 51% faster fitting t
NEURA Robotics Introduces Neuron AI: The Brain of the Physical World14.10.2026 09:29:00 EEST | Press release
NEURA Robotics (“NEURA”) today introduced Neuron AI, its multimodal foundation model for Physical AI. Combining 3D vision, touch, audio, robot state and language with memory, Neuron AI enables robots to act on information beyond what cameras alone can capture, as well as retain relevant context when objects disappear from view. Its Perception-Language-Action (PLA) architecture connects what a robot sees, hears and feels with what it has already done, turning multisensory information into physical action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013482085/en/ Neuron AI: The Brain of the Physical World “An intelligent robot needs a brain that brings its senses together and remembers what happened,” said David Reger, Founder and CEO of NEURA Robotics. “With Neuron AI, we are building the brain of the physical world: Physical AI that turns human expertise and physical experience into capabilities robots can learn and ap
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering14.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built on clinical science and protocol-based daily care, from its shareholders, including funds managed by Blackstone Tactical Opportunities (“Blackstone”) and the Obagi family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013945338/en/ Founded by dermatologist Dr. Zein Obagi and headquartered in Irvine, California, ZO Skin Health has been a reference name in clinically-backed professional skincare for more than two decades. Its broad product portfolio, spanning over 40 products, is manufactured in the U.S. and sold through a network of more than 16,500 physician, medical spa and online accounts across more than 40 countries, supported by a dedicated salesforce and skincare education team. ZO Skin Health recorded net sales of approximately 330 million USD in the last twelve months
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom